^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEN3017

    i
    Other names: GEN3017, DuoBody-CD3xCD30
    Associations

    News

    Trials
    Company:
    Genmab
    Drug class:
    CD3 agonist, CD30 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=240, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    GEN3017
    1year
    A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=240, Recruiting, Genmab | Trial completion date: Jun 2028 --> Dec 2032
    Trial completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    GEN3017
    1year
    A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=240, Recruiting, Genmab | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    GEN3017
    over1year
    A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=240, Not yet recruiting, Genmab
    New P1/2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    GEN3017
    2years
    Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies (ASH 2022)
    In the last decade, treatment regimen including brentuximab vedotin have significantly improved prognosis for patients with CD30-expressing lymphomas...Here, we report preclinical data for the novel DuoBody®-CD3xCD30 (GEN3017), a CD3 bsAb targeting CD30-expressing tumor cells...CD30-expressing HL (L428) and ALCL (KI-JK) tumor cell lines were incubated with purified healthy donor T cells (E:T ratio = 4:1) and DuoBody-CD3xCD30 or bsIgG1-CD3xctrl for 72 hours. T-cell mediated cytotoxicity was measured by flow cytometry and expressed as the percentage viable tumor cells normalized to an untreated control sample.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin) • GEN3017